Arvinas Inc
ARVN7.230USD
-2.389-24.84%
收盘 05/01, 16:00（美东）报价延迟15分钟
497.42M总市值
亏损市盈率 TTM
关于 Arvinas Inc 公司
Arvinas, Inc. 是一家临床阶段的生物技术公司。该公司通过其 PROteolysis Targeting Chimera (PROTAC) 蛋白质降解剂平台，率先开发蛋白质降解疗法，旨在利用人体的天然蛋白质处理系统选择性高效地降解和去除致病蛋白质。该公司正在通过临床开发项目推进多种研究药物，包括 vepdegestrant、ARV-393 和 ARV-102。Vepdegestrant 是一种口服生物可利用的 PROTAC 蛋白质降解剂，旨在靶向和降解 ER，用于治疗局部晚期或转移性 ER+/HER2- 乳腺癌患者。该公司正在与辉瑞共同开发 vepdegestrant。ARV-393 是一种口服生物可利用的 PROTAC，旨在降解 BCL6，这是一种转录抑制因子和正常 B 细胞成熟和分化过程的关键调节剂。ARV-102 正在开发中，用于治疗神经退行性疾病。
公司简介
公司代码ARVN
公司名称Arvinas Inc
上市日期- -
成立日期- -
CEO- -
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
国家- -
邮编- -
电话- -
网址- -
公司代码ARVN
上市日期- -
成立日期- -
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
5.90K
--
Mr. Jared Morris Freedberg
Mr. Jared Morris Freedberg
General Counsel
General Counsel
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
John Young ,
John Young ,
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
收入明细
FY2024
FY2023
暂无数据
地区USD
名称
营收
占比
United States
263.40M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 2月28日 周五
更新时间: 2月28日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
持股股东
股东统计
占比
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
40.57%
Investment Advisor
35.44%
Hedge Fund
18.71%
Corporation
4.76%
Venture Capital
3.17%
Research Firm
2.67%
Individual Investor
2.42%
Sovereign Wealth Fund
1.70%
Private Equity
1.52%
机构持股
更新时间: 3月3日 周一
更新时间: 3月3日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q1
493
81.65M
117.98%
-2.97M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
2022Q4
484
56.43M
106.14%
-6.62M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
7.05M
10.26%
+56.56K
+0.81%
Dec 31, 2024
EcoR1 Capital, LLC
6.73M
9.78%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.29M
7.69%
+152.31K
+2.97%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.02M
5.85%
+289.37K
+7.75%
Dec 31, 2024
Citadel Advisors LLC
3.48M
5.06%
+407.46K
+13.26%
Jan 30, 2025
Pfizer Inc
3.46M
5.03%
--
--
Dec 31, 2024
RTW Investments L.P.
3.33M
4.85%
+551.98K
+19.84%
Dec 31, 2024
Bellevue Asset Management AG
2.39M
3.47%
+3.00K
+0.13%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.21M
3.21%
+2.21M
--
Dec 31, 2024
UBS Financial Services, Inc.
2.01M
2.93%
+1.54M
+329.49%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
SPDR S&P Pharmaceuticals ETF
1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
Range Cancer Immunotherapy ETF
1.24%
Tema Oncology ETF
0.97%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
Zacks Small/Mid Cap ETF
0.42%
JPMorgan Fundamental Data Science Small Core ETF
0.33%
Tema Neuroscience and Mental Health ETF
0.33%
iShares Health Innovation Active ETF
0.22%
iShares U.S. Pharmaceuticals ETF
0.18%
查看更多
SPDR S&P Pharmaceuticals ETF
占比1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.35%
Range Cancer Immunotherapy ETF
占比1.24%
Tema Oncology ETF
占比0.97%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.8%
Zacks Small/Mid Cap ETF
占比0.42%
JPMorgan Fundamental Data Science Small Core ETF
占比0.33%
Tema Neuroscience and Mental Health ETF
占比0.33%
iShares Health Innovation Active ETF
占比0.22%
iShares U.S. Pharmaceuticals ETF
占比0.18%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据